CareDx — Third Quarter 2026 Earnings Summary

CareDx reported third-quarter 2026 revenue of $139 million, representing a 39% year-over-year increase driven by growth in testing services and the inclusion of Specialty Oncology revenue following the acquisition of Naveris. The company achieved a GAAP net income of $19 million and an Adjusted EBITDA of $30 million, while raising its full-year 2026 revenue guidance to a range of $520 million to $530 million. Testing services volume reached approximately 75,900 tests, a 51% increase year-over-year, and the company advanced its AlloHeme and HistoMap Kidney products toward commercial launches in 2027.